Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Pharmacological interventions for dementia include medications aimed at alleviating its core symptom: cognitive dysfunction.
-
Second-generation anti-amyloid therapies (ATTs) offer new options for early Alzheimer's disease treatment, but with modest efficacy and documented adverse events.
-
The approvals of the first anti-amyloid antibodies for the treatment of Alzheimer's disease have changed both the clinical and research landscape for the disease.
-
On 22 May 2025, the Therapeutic Goods Administration (TGA) announced that the anti-amyloid monoclonal antibody donanemab (Eli Lilly, Kisunla) was approved in Australia for the treatment of Alzheimer's disease (AD).
-
The introduction of anti-amyloid antibodies has ushered in a new era in the treatment of Alzheimer's disease (AD), coinciding with the revision of its diagnostic criteria, which now focus on the biological definition of AD, with amyloid beta at its core.
-
With this notice, the Internation Journal of Molecular Sciences Editorial Office states their awareness of the concerns regarding the integrity of a number of the figures published within this publication [...].
-
Anti-amyloid monoclonal antibodies (MABs) have introduced a new era of Alzheimer's disease (AD) therapeutics with disease-targeted drugs.
-
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease.
-
Tirzepatide could control postprandial hyperglycemia even in cases with diminished β-cell function.
-
Experimental drugs lowering brain tau are heralded as improvements in the treatment of Alzheimer's disease.
-
Type 2 Diabetes Mellitus therapy has evolved over the years to now include a new class of therapeutics, semaglutide.
-
43/100
Seizures in people with Alzheimer's disease are increasingly recognized to worsen disease burden and accelerate functional decline.
-
Psychosis and agitation are among the most distressing neuropsychiatric symptoms (NPSs) of Alzheimer's disease (AD), linked to faster disease progression and earlier admission to nursing homes.
-
Symptom-oriented treatment has been the mainstay of Alzheimer disease (AD) pharmacotherapy for decades.
-
Insomnia has now become a major health problem of global concern, with about 1/3 of the population suffering from sleep problems, a proportion that is still rising year by year.
-
Medical science has made revolutionary discoveries around the nosology and aetiology of the neurodegenerative diseases.
-
Alzheimer's disease (AD) is the most common neurodegenerative disorder, and for providers the term AD is often avoided, favoring generic terms like memory loss or dementia.
-
43/100
The 75th anniversary of introducing lithium into modern psychiatry is recognized, attested by the 1949 paper of John Cade.
-
Advances in amyloid targeting therapies (ATT) for Alzheimer's disease have introduced new options, necessitating an understanding of physicians' perspectives as these therapies move from trials to practice.
-
The recent rejection of lecanemab by the European Medicines Agency despite its approval in other countries highlights the debate among researchers and regulatory bodies about the efficacy, safety, and underlying scientific basis of drugs to treat Alzheimer’s disease. [Image: see text]
-
The prevalence of neurocognitive disorders (NCD) increases every year as the population continues to age, leading to significant global health concerns.
-
Worldwide, around 50 million people live with dementia, and this number is projected to triple by 2050.
-
Alzheimer disease is a progressive, neurodegenerative disorder characterized by the accumulation of amyloid beta plaques and hyperphosphorylated tau proteins.
-
Overly restrictive clinical trial eligibility criteria can reduce generalizability, slow enrollment, and disproportionately exclude historically underrepresented populations.
-
Recent guidance from the American Society of Anesthesiologists demonstrates the importance of tailored management of GLP-RA drugs for surgical patients.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial
- Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease
- Metformin use and brain atrophy in nondemented elderly individuals with diabetes
- Donanemab for Alzheimer's disease: from preclinical research to the clinical application
- Use of anticholinergic medications by older adults with dementia
- Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors
- Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management
- A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity
- Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)
- Network-based stage-specific drug repurposing for Alzheimer's disease